Synapse - Advanced Practice Providers

Results (105)

Phase II trial of pembrolizumab plus gemcitabine, vinorelbine, and liposomal doxorubicin as second-line therapy for relapsed or refractory classical Hodgkin lymphoma

Journal Article

Moskowitz, A. J.; Shah, G.; Schöder, H.; Ganesan, N.; Drill, E.; Hancock, H.; Davey, T.; Perez, L.; Ryu, S.; Sohail, S.; more...
Journal of Clinical Oncology (2021)

Fulltext@MSK | Save

Predictors of humoral response to SARS-CoV-2 vaccination after hematopoietic cell transplantation and CAR T-cell therapy

Journal Article

Tamari, R.; Politikos, I.; Knorr, D. A.; Vardhana, S. A.; Young, J. C.; Marcello, L. T.; Doddi, S.; Devlin, S. M.; Ramanathan, L. V.; Pessin, M. S.; more...
Blood Cancer Discovery (2021)

Fulltext@MSK | Save

Zanubrutinib, obinutuzumab, and venetoclax with minimal residual disease-driven discontinuation in previously untreated patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: A multicentre, single-arm, phase 2 trial

Journal Article

Soumerai, J. D.; Mato, A. R.; Dogan, A.; Seshan, V. E.; Joffe, E.; Flaherty, K.; Carter, J.; Hochberg, E.; Barnes, J. A.; Hamilton, A. M.; more...
The Lancet Haematology (2021)

Fulltext@MSK | Save

Romidepsin and lenalidomide-based regimens have efficacy in relapsed/refractory lymphoma: Combined analysis of two phase I studies with expansion cohorts

Journal Article

Mehta-Shah, N.; Lunning, M. A.; Moskowitz, A. J.; Boruchov, A. M.; Ruan, J.; Lynch, P.; Hamlin, P. A.; Leonard, J.; Matasar, M. J.; Myskowski, P. L.; more...
American Journal of Hematology (2021)

Fulltext@MSK | Save

Modified EASIX predicts severe cytokine release syndrome and neurotoxicity after chimeric antigen receptor T cells

Journal Article

Pennisi, M.; Sanchez-Escamilla, M.; Flynn, J. R.; Shouval, R.; Alarcon Tomas, A.; Silverberg, M. L.; Batlevi, C.; Brentjens, R. J.; Dahi, P. B.; Devlin, S. M.; more...
Blood Advances (2021)

Fulltext@MSK | Save

A phase II trial of reduced dose brentuximab vedotin for cutaneous T‐cell lymphomas

Meeting Abstract

Khan, N.; Noor, S.; Geller, S.; Khodadoust, M. S.; Kheterpal, M.; Hancock, H.; Davey, T.; Ryu, S.; Perez, L.; Lares, A.; more...
Hematological Oncology (2021)

Fulltext@MSK | Save

The combination of duvelisib and romidepsin (DR) is highly active against relapsed/refractory peripheral T‐cell lymphoma with low rates of transaminitis: Final results

Meeting Abstract

Horwitz, S. M.; Moskowitz, A. J.; Mehta‐Shah, N.; Jacobsen, E. D.; Khodadoust, M. S.; Ganesan, N.; Drill, E.; Hancock, H.; Davey, T.; Myskowski, P.; more...
Hematological Oncology (2021)

Fulltext@MSK | Save

Phase I study of bendamustine, rituximab, ibrutinib, and venetoclax in relapsed, refractory mantle cell lymphoma

Meeting Abstract

Kumar, A.; Batlevi, C.; Drullinsky, P.; Grieve, C.; Laraque, L.; Joseph, A.; Mahajan, N.; Matasar, M.; Straus, D.; Zelenetz, A.; more...
Hematological Oncology (2021)

Fulltext@MSK | Save

Noninvasive monitoring of mantle cell lymphoma by immunoglobulin gene next-generation sequencing in a phase 2 study of sequential chemoradioimmunotherapy followed by autologous stem-cell rescue

Journal Article

Kumar, A.; Bantilan, K. S.; Jacob, A. P.; Park, A.; Schoninger, S. F.; Sauter, C.; Ulaner, G. A.; Casulo, C.; Faham, M.; Kong, K. A.; more...
Clinical Lymphoma, Myeloma and Leukemia (2021)

Fulltext@MSK | Save

The International Prognostic Index is associated with outcomes in diffuse large B cell lymphoma after chimeric antigen receptor T cell therapy

Journal Article

Garcia-Recio, M.; Wudhikarn, K.; Pennisi, M.; Alonso-Trillo, R.; Flynn, J.; Shouval, R.; Afuye, A. O.; Silverberg, M. L.; Batlevi, C. W.; Dahi, P.; more...
Transplantation and Cellular Therapy (2021)

Fulltext@MSK | Save